Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Aachen – page 33

1 286 clinical trials in Aachen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Aachen at a glance
1 286
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 286 trials in Aachen

Open in trial search

Rhabdomyosarcoma

Recruiting

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:The University Of Birmingham

Non-small cell lung cancer

Recruiting

Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Acute respiratory distress syndrome

Recruiting

Study on the Safety and Benefits of Recombinant Human Plasma Gelsolin for Patients with Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Bioaegis Therapeutics Inc.

Pulmonary sarcoidosis

Recruiting

Study on Methotrexate and Prednisone for Treating Lung Sarcoidosis in Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Methotrexate
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Dry age-related macular degeneration

Recruiting

Study on Long-term Safety of JNJ-81201887 for Patients with Geographic Atrophy Due to Age-related Macular Degeneration

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Janssen Cilag International

Mitochondrial myopathy

Recruiting

Study on the Effect and Safety of Autologous Mesoangioblasts for Patients with Mitochondrial Myopathy Due to m.3243A>G Mutation

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Sponsor:University Hospital Maastricht

Small intestine adenocarcinoma

Recruiting

Study on the Effectiveness of Fluorouracil, Levoleucovorin, and Oxaliplatin in Patients with Resected Small Bowel Adenocarcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Groupe Belge D'Oncologie Digestive

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Institut Gustave Roussy

Human papilloma virus immunisation+1

Recruiting

Study on HPV Vaccine for Women with Vulvar HSIL: Evaluating the Effectiveness of Nonavalent HPV Vaccine in Preventing Recurrence of Vulvar High-Grade Lesions

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Non-small cell lung cancer

Recruiting

Study on Modified Osimertinib Dosing with Cobicistat for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cobicistat
  • Sponsor:University Hospital Maastricht

Non-small cell lung cancer

Recruiting

Study Comparing Standard and Adjusted Doses of Alectinib for Patients with ALK Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:Universitair Medisch Centrum Groningen

Plasma cell myeloma

Recruiting

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Aachen

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on lymphoma treatments and various forms of breast cancer therapies, including studies of novel immunotherapy combinations for head and neck cancers.

  • Diffuse Large B-Cell Lymphoma
  • Triple-Negative Breast Cancer
  • Non-small Cell Lung Cancer

Advanced therapeutic approaches including targeted treatments and combination therapies are being evaluated for improved patient outcomes.

02 Cardiovascular Studies

Research targeting heart failure prevention and management of cardiovascular complications, with emphasis on innovative drug combinations and preventive treatments.

  • Heart Failure Prevention
  • Cardiovascular Disease Management
  • Obesity-related Cardiac Conditions

Studies focus on reducing cardiovascular events and improving long-term patient outcomes.

03 Chronic Conditions

Clinical investigations addressing various chronic conditions, including inflammatory diseases and dermatological disorders.

  • Hidradenitis Suppurativa
  • Chronic Venous Ulcers
  • Inflammatory Myopathies

Evaluating new therapeutic approaches for managing long-term conditions and improving quality of life.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.